Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., explained in plain language.
A biopharmaceutical company developing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced cancer: first human trial of FZ-AD004 begins Results expected Dec 2026 (estimated)
- New light therapy could fade Port-Wine stains Results expected Jan 2027 (estimated)
-
New drug candidate targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…
Phase 1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug aimed at tough breast cancer enters final testing phase
Disease control OngoingThis phase 3 trial tests a new drug called FDA018-ADC against standard chemotherapy in 350 people with advanced triple-negative breast cancer that has worsened after taxane treatment. The study compares how long the cancer stays under control and overall survival. Participants ar…
Phase 3 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC